APT™ T3X on the COVID-19 Contamination Rate
ClinicalTrials.gov; 18/01/2021; TrialID: NCT04716426
Clinical Trial Register
| ICTRP | ID: ictrp-NCT04716426
ABSTRACT
Condition
COVID-19Intervention
Drug Tetracycline hydrochloride 3%;Drug PlaceboPrimary outcome:
COVID-19 Contamination Rate.Criteria
Inclusion Criteria
- good general health (without serious health problems);
- tested negative, by means of immunoglobulin (Ig) G and IgM serology tests and chain
real-time polymerase chain reaction (RT-PCR), for COVID-19.
Exclusion Criteria
- previous immunization against COVID-19;
- allergy to tetracycline hydrochloride;
- diagnosis of Lyme disease;
- immunocompromised;
- share housing with someone diagnosed with COVID-19 at the time of the baseline
evaluation;
- serious illnesses, such as cancer, kidney failure, decompensated cardiorespiratory and
metabolic diseases, etc.
Collection:
Clinical trial registers
Database:
ICTRP
Year:
2021
Document Type:
Clinical Trial Register
Similar
MEDLINE
...
LILACS
LIS